SLDB — Solid Biosciences LLC
NASDAQ · Healthcare · Biotechnology
$9.88
+$0.30 (+3.13%)
Solid Biosciences LLC (SLDB) is a biotechnology company listed on NASDAQ. It is led by Alexander G. Cumbo, based in 500 Rutherford Avenue, Charlestown, MA, United States, 02129, with about 100 employees. Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Net income was -$45.8M. SLDB currently screens at market cap $389.9M.
Use this SLDB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SLDB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SLDB SEC filings page. Lician reads the product cache first so this HTML stays unique to Solid Biosciences LLC even when a live quote feed is slow.
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
SLDB Key Statistics
Market Cap
$389.90M
Volume
1.26M
Previous Close
$9.16
Day Range
$9.33 – $9.90
EPS
-$3.06
Revenue
$0.00
Net Income
-$124.70M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
100
SLDB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $8.09M | $13.62M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$124.70M | -$96.02M | -$85.98M | -$72.19M |
| EPS (Diluted) | -$3.06 | -$4.83 | -$10.10 | -$10.14 |
Total Assets
$188.66M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$80.23M
Operating Cash Flow
-$100.01M
Free Cash Flow
$0.00
Solid Biosciences LLC Company Information
- President, CEO & Director
- Alexander G. Cumbo
- Headquarters
- 500 Rutherford Avenue, Charlestown, MA, United States, 02129
- Website
- www.solidbio.com
- Phone
- 617 337 4680
- IPO / Founded
- 2018-01-26
- Sector
- Healthcare
- Industry
- Biotechnology